STOCK TITAN

Leap Therapeutic SEC Filings

LPTX NASDAQ

Welcome to our dedicated page for Leap Therapeutic SEC filings (Ticker: LPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Cypherpunk Technologies Inc. filings document the issuer's transition from Leap Therapeutics, its Zcash-focused digital asset treasury activity, and formal public-company reporting after the name change. Current reports cover financial results, ZEC purchases, material agreements, equity offering arrangements, capital-structure disclosures, and Nasdaq listing-compliance notices.

Proxy materials cover annual meeting voting and board governance for the renamed company. The filing record also preserves disclosure categories tied to the company's prior oncology identity, including corporate status, risk factors, financing arrangements, and governance matters connected to its continuing subsidiary-based therapeutic research operations.

Rhea-AI Summary

Cypherpunk Technologies Inc. reported that it has expanded its cryptocurrency treasury by purchasing an additional $18 million of Zcash (ZEC) on November 18, 2025. This new purchase totals 29,869.29 ZEC at an average price of $602.63 per ZEC. The company previously acquired 203,775.27 ZEC for approximately $50 million at an average price of $245.37 per ZEC. After the latest transaction, Cypherpunk now holds 233,644.56 ZEC at an overall average cost of $291.04 per ZEC, representing 1.43% ownership of the Zcash network.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Cypherpunk Technologies Inc. (CYPH) reported an insider equity grant on a Form 4. On 11/11/2025, Director and officer Douglas E. Onsi received 2,087,287 restricted stock units (RSUs) under the company’s 2016 Equity Incentive Plan for $0 consideration.

The RSUs vest as follows: 12/36th on October 8, 2026 and 1/36th on the 8th day of each month thereafter, subject to continued service. Vested RSUs will be settled in common stock at the earliest of: the first payroll period after the end of the reporting person’s employment or service, the first payroll period on or after the 8th day of June following any applicable Vesting Date, or the first payroll period on or after the 8th day of December following any applicable Vesting Date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cypherpunk Technologies Inc. (CYPH) reported a director equity grant. On November 11, 2025, the director received 74,700 restricted stock units (RSUs) under the Company’s 2022 Equity Incentive Plan for no consideration, each RSU deliverable into one share of common stock.

The RSUs vested at issuance on the grant date. Settlement into common shares will occur as soon as practicable after the earlier of the fifth business day following the director’s service ending or the first annual meeting of stockholders following the grant date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Cypherpunk Technologies Inc. (CYPH) reported a director equity grant. A Form 4 discloses an award of 74,700 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan. Each RSU converts into one share of common stock, par value $0.001, and the award was granted for no consideration.

The RSUs vested at issuance on the grant date and will be settled in common stock as soon as practicable after the earlier of (i) the fifth business day following the director’s departure from the Board or (ii) the first annual meeting of stockholders following the grant date. Following the reported transaction, the director holds 74,700 derivative securities on a direct ownership basis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cypherpunk Technologies (CYPH) reported a director equity grant on Form 4. On November 11, 2025, the director received 74,700 restricted stock units (RSUs) for no cash consideration under the 2022 Equity Incentive Plan. The RSUs vested at issuance.

Settlement into common stock will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the Board or the first annual stockholder meeting after the grant date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cypherpunk Technologies Inc. (CYPH) reported an insider equity grant. A director received 74,700 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan for $0 consideration, with each RSU settling 1-for-1 into common stock.

The RSUs vested at issuance. Settlement will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the board or the first annual meeting of stockholders following the grant date. Following the transaction, the filing lists 74,700 derivative securities held direct.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Cypherpunk Technologies Inc. (CYPH) filed a Form 4 reporting an equity grant to a director. On November 11, 2025, the reporting person was awarded 74,700 restricted stock units (RSUs) priced at $0 under the company’s 2022 Equity Incentive Plan.

The RSUs vested at issuance on the grant date, with settlement in common stock on a one-for-one basis. Settlement will occur as soon as practicable after the earlier of the fifth business day following the director’s departure from the Board or the first annual meeting of stockholders after the grant date, subject to applicable tax withholdings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cypherpunk Technologies Inc. (CYPH) reported a director equity award on Form 4. The reporting person received 74,700 restricted stock units (RSUs) on November 11, 2025 at an exercise price of $0, granted under the company’s 2022 Equity Incentive Plan.

The RSUs vested at issuance on the grant date and will be settled in common stock on the earlier of the fifth business day after the reporting person ceases to serve on the board or the first annual meeting of stockholders following the grant date. Following the transaction, the reporting person holds 74,700 derivative securities directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cypherpunk Technologies Inc. (CYPH) reported a director equity grant on a Form 4. On November 11, 2025, the director received 74,700 restricted stock units (RSUs) awarded for $0 under the company’s 2016 Equity Incentive Plan.

The RSUs vested at issuance on the grant date and will be settled in common stock after the earlier of the fifth business day following the director’s service end or the first annual stockholders’ meeting after the grant. Following the transaction, the reporting person beneficially owned 74,700 derivative securities, held directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Cypherpunk Technologies Inc. (CYPH) reported a director’s equity grant on a Form 4. The director received 83,000 restricted stock units (RSUs) on November 11, 2025 under the company’s 2022 Equity Incentive Plan for $0 consideration.

The RSUs vested at issuance on the grant date. Settlement into common stock will occur as soon as practicable after the earlier of the fifth business day following the director’s service end or the first annual stockholder meeting following the grant date. The RSUs are shown as direct (D) ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

How many Leap Therapeutic (LPTX) SEC filings are available on StockTitan?

StockTitan tracks 48 SEC filings for Leap Therapeutic (LPTX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Leap Therapeutic (LPTX)?

The most recent SEC filing for Leap Therapeutic (LPTX) was filed on November 18, 2025.